Celldex Therapeutics Files 2024 10-K
Ticker: CLDX · Form: 10-K · Filed: Feb 27, 2025 · CIK: 744218
| Field | Detail |
|---|---|
| Company | Celldex Therapeutics, Inc. (CLDX) |
| Form Type | 10-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, biotech, annual-report
TL;DR
Celldex 2024 10-K is in. Full financials and biz update for investors.
AI Summary
Celldex Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, detailing its financial performance and business operations for the fiscal year ending December 31, 2024. The company, formerly known as AVANT IMMUNOTHERAPEUTICS INC and T CELL SCIENCES INC, is focused on the development of novel therapeutics. Key financial data and operational highlights for 2024 are presented in this annual report.
Why It Matters
This filing provides investors and the public with a comprehensive overview of Celldex Therapeutics' financial health, strategic direction, and potential risks for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a biotechnology company, Celldex Therapeutics faces inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 000-15006 — SEC File Number (Identifies the company's filings with the SEC.)
- 0000744218 — Central Index Key (Unique identifier for the company in SEC filings.)
Key Players & Entities
- Celldex Therapeutics, Inc. (company) — Filer of the 10-K
- AVANT IMMUNOTHERAPEUTICS INC (company) — Former company name
- T CELL SCIENCES INC (company) — Former company name
- 2024-12-31 (date) — Fiscal year end
- 20250227 (date) — Filing date
FAQ
What is Celldex Therapeutics' primary business focus as detailed in the 2024 10-K?
The filing indicates Celldex Therapeutics is focused on the development of novel therapeutics, as suggested by its SIC code 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]' and its history.
When did Celldex Therapeutics file its 2024 10-K report?
Celldex Therapeutics filed its 2024 10-K report on February 27, 2025.
What were the previous names of Celldex Therapeutics, Inc.?
Celldex Therapeutics, Inc. was formerly known as AVANT IMMUNOTHERAPEUTICS INC and T CELL SCIENCES INC.
What is the company's principal business address?
The company's business address is 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ 08827.
What is the fiscal year end for Celldex Therapeutics?
The fiscal year end for Celldex Therapeutics is December 31.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding Celldex Therapeutics, Inc. (CLDX).